UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000017912 |
|---|---|
| Receipt number | R000020761 |
| Scientific Title | Combined use of long-acting insulin analogue, GLP-1 receptor agonist, and sulfonylurea in type 2 diabetes |
| Date of disclosure of the study information | 2015/06/15 |
| Last modified on | 2016/02/10 12:29:03 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Combined use of long-acting insulin analogue, GLP-1 receptor agonist, and sulfonylurea in type 2 diabetes
Acronym
Combined use of long-acting insulin analogue, GLP-1 receptor agonist, and sulfonylurea in type 2 diabetes
Scientific Title
Combined use of long-acting insulin analogue, GLP-1 receptor agonist, and sulfonylurea in type 2 diabetes
Scientific Title:Acronym
Combined use of long-acting insulin analogue, GLP-1 receptor agonist, and sulfonylurea in type 2 diabetes
Region
| Japan |
Condition
Condition
type 2 diabetes mellitus
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To investigate quality of life after switching to the combination therapy of long-acting insulin, GLP-1 receptor agonist, and sulfonylurea in type 2 diabetic patients treated with long-acting insulin plus multiple oral hypoglycemic agents
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Diabetes therapy-related QOL
Key secondary outcomes
- Medication adherance
- Hemoglobin A1c, Blood glucose
- Body weight
- safety
- Cost
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
To switch to the combination therapy of a long-acting insulin, a GLP-1 receptor agonist liraglutide, and a sulfonylurea glimepiride
Interventions/Control_2
To continue the combination therapy of a long-acting insulin and multiple oral hypoglycemic agents
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients treated with the combined therapy of a long-acting insulin analogue and multiple oral hypoglycemic agents including a sulfonylurea, a DPP-4 inhibitor and metformin
Key exclusion criteria
- Patients with severe hepatic, renal, and/or cardiac disease
- Patients with hypersentitivity to the agents used in the current study
- Patients who are pregnant, breast-feeding or may become pregnant
- Patients who are judged by the investigator to be inappropriate for this study for any other reason.
Target sample size
70
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Toshihiko Shiraiwa/Mitsuyoshi Takahara |
Organization
Shiraiwa Medical Clinic/Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine
Division name
Shiraiwa Medical Clinic/Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine
Zip code
Address
4-10-24 Hozenji, Kashiwara, Osaka 582-0005, Japan
TEL
072-971-1221
takahara@endmet.med.osaka-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Toshihiko Shiraiwa |
Organization
Shiraiwa Medical Clinic
Division name
Shiraiwa Medical Clinic
Zip code
Address
4-10-24 Hozenji, Kashiwara, Osaka 582-0005, Japan
TEL
072-971-1221
Homepage URL
takahara@endmet.med.osaka-u.ac.jp
Sponsor or person
Institute
Shiraiwa Medical Clinic
Institute
Department
Personal name
Funding Source
Organization
Shiraiwa Medical Clinic
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2015 | Year | 06 | Month | 15 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2015 | Year | 02 | Month | 25 | Day |
Date of IRB
Anticipated trial start date
| 2015 | Year | 06 | Month | 15 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2015 | Year | 06 | Month | 15 | Day |
Last modified on
| 2016 | Year | 02 | Month | 10 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020761
